相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Letter
Hematology
Albrecht Betrains et al.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Medicine, General & Internal
Robert L. Gottlieb et al.
Summary: The study showed that treatment with bamlanivimab and etesevimab was significantly associated with a reduction in SARS-CoV-2 viral load at day 11 in nonhospitalized patients with mild to moderate COVID-19, compared to placebo. However, bamlanivimab monotherapy did not show a significant reduction in viral load. Ongoing clinical trials will focus on assessing the clinical benefits of antispike neutralizing antibodies in COVID-19 patients.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Oncology
Silvia Ferrari et al.
Summary: This study described the use of hyperimmune plasma therapy in immunocompromised patients with hematological disorders during the SARS-CoV-2 outbreak, showing positive outcomes such as clinical improvement, recovery, and viral clearance. While further research is needed, the results suggest a specific role for hyperimmune plasma therapy in hematological patients.
LEUKEMIA & LYMPHOMA
(2021)
Article
Biochemistry & Molecular Biology
Daming Zhou et al.
Summary: The race to develop vaccines against SARS-CoV-2 variants, such as B.1.1.7, B.1.351, and P.1, is ongoing as these variants have mutations in the spike protein, potentially leading to immune escape. A structure-function analysis of B.1.351 revealed tighter ACE2 binding and widespread evasion from monoclonal antibody neutralization, particularly driven by the E484K mutation.
Article
Microbiology
Zhuoming Liu et al.
Summary: The study found that antibodies targeting the SARS-CoV-2 spike protein have escape mutations, different monoclonal antibodies have unique resistance profiles, some mutants are resistant to multiple antibodies while some variants can escape neutralization by convalescent sera. Comparing antibody-mediated mutations with circulating SARS-CoV-2 sequences revealed substitutions that may weaken neutralizing immune responses in some individuals, warranting further investigation.
CELL HOST & MICROBE
(2021)
Article
Oncology
Marc S. Hoffmann et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2021)
Article
Biochemistry & Molecular Biology
Rita E. Chen et al.
Summary: The study analyzed antibody neutralization activity against a panel of authentic isolates and chimeric SARS-CoV-2 variants, showing significantly reduced neutralizing activity against the B.1.351 variant first identified in South Africa. Antibodies targeting the receptor-binding domain and N-terminal domain, monoclonal antibodies, convalescent sera, and mRNA vaccine-induced immune sera exhibited decreased inhibitory activity against viruses with an E484K spike mutation, suggesting a need for updated monoclonal antibodies or vaccine adjustments to prevent loss of protection against emerging variants.
Article
Hematology
Remy Dulery et al.
Summary: Age >= 70 years, relapsed/refractory lymphoma, and recent administration of anti-CD20 therapy are risk factors for prolonged length of in-hospital stay and death for lymphoma patients hospitalized for Covid-19.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Article
Oncology
Anna Furlan et al.
Summary: Four NHL patients with SARS-CoV-2 pneumonia after rituximab therapy showed early relapse and prolonged disease course despite initial treatment with remdesivir and steroids, but had rapid and significant response to convalescent hyperimmune plasma and extended course of remdesivir. These clinical observations suggest that the immunological effects of rituximab treatment in NHL patients should be considered for proper choice of SARS-CoV-2 laboratory tests and guiding therapeutic approaches.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2021)
Article
Hematology
Erik Gaitzsch et al.
Summary: B-cell depleted lymphoma patients with COVID-19 experienced more severe and prolonged clinical course, with early activation of monocytes/macrophages, neutrophils, and the complement system, exacerbation of inflammatory response, and dysfunctional interferon signaling leading to clinical deterioration. Additionally, these patients showed SARS-CoV-2-specific T-effector cell responses but struggled with long-term viral shedding and inability to sustain lasting antibody responses.
Letter
Infectious Diseases
Sonia Jangra et al.
Article
Cell Biology
Tyler N. Starr et al.
Summary: The study mapped mutations to the SARS-CoV-2 spike receptor-binding domain that escape binding by certain monoclonal antibodies. These mutations are concentrated in specific lineages of SARS-CoV-2. The authors suggest diversifying the epitopes targeted by antibodies and antibody cocktails to make them more resilient to SARS-CoV-2 antigenic evolution.
CELL REPORTS MEDICINE
(2021)
Review
Immunology
Peter C. Taylor et al.
Summary: The study discusses the clinical utility of neutralizing monoclonal antibody therapies targeting SARS-CoV-2, emphasizing the importance of patient stratification, biomarkers, risk factors, and other clinical considerations.
NATURE REVIEWS IMMUNOLOGY
(2021)
Article
Biology
Yiska Weisblum et al.
Review
Dentistry, Oral Surgery & Medicine
Yu-Chen Jiang et al.
INTERNATIONAL JOURNAL OF ORAL SCIENCE
(2016)
